Construction, expression, purification, and characterization of a dual-targeting PD-1/VEGF-A fusion protein (P-V)

Protein Expression and Purification

Volumn 109, Issue , 2015, Pages 1-6

  Qian, Niliang ^a,b   Gao, Liucun ^b   Dong, Lihou ^b   Liu, Hongchuan ^c   Fu, Jie ^b   Meng, Dan ^c   Gao, Xin ^b   Zhang, Jing ^c   Gao, Yucai ^c   Song, Haifeng ^a,b  

^a ANHUI MEDICAL UNIVERSITY   (China)

^b BEIJING INSTITUTE OF RADIATION MEDICINE   (China)

^c Suzhou Junmeng Biosciences Co Ltd   (China)

Author keywords

293E cells; Anti tumor; Dual targeting; Fusion protein; PD 1; VEGF A

Indexed keywords

HYBRID PROTEIN; PROGRAMMED DEATH 1 RECEPTOR; VASCULOTROPIN A;

CHEMISTRY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE VECTOR; HUMAN; ISOLATION AND PURIFICATION; METABOLISM; POLYACRYLAMIDE GEL ELECTROPHORESIS; POLYMERASE CHAIN REACTION; PROCEDURES; PROTEIN ENGINEERING; UMBILICAL VEIN ENDOTHELIAL CELL; WESTERN BLOTTING;

BLOTTING, WESTERN; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENETIC VECTORS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; POLYMERASE CHAIN REACTION; PROGRAMMED CELL DEATH 1 RECEPTOR; PROTEIN ENGINEERING; RECOMBINANT FUSION PROTEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84921992476     PISSN: 10465928     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pep.2015.01.004     Document Type: Article

References (30)

1. Y. Ishida, Y. Agata, K. Shibahara, T. Honjo, Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death, EMBO J. 11 (1992) 3887-3895.
2. H. Nishimura, Y. Agata, A. Kawasaki, M. Sato, S. Imamura, N. Minato, H. Yagita, T. Nakano, T. Honjo, Developmentally regulated expression of the PD-1 protein on the surface of double-negative (CD4-CD8-) thymocytes, Int. Immunol. 8 (1996) 773-780.
3. L. Chen, Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity, Nat. Rev. Immunol. 4 (2004) 336-347.
4. M.E. Keir, M.J. Butte, G.J. Freeman, A.H. Sharpe, PD-1 and its ligands in tolerance and immunity, Annu. Rev. Immunol. 26 (2008) 677-704.
5. N. Patsoukis, D. Sari, V.A. Boussiotis, PD-1 inhibits T cell proliferation by upregulating p27 and p15 and suppressing Cdc25A, Cell Cycle 11 (2012) 4305-4309.
6. K.A. Sheppard, L.J. Fitz, J.M. Lee, C. Benander, J.A. George, J. Wooters, Y. Qiu, J.M. Jussif, L.L. Carter, C.R. Wood, D. Chaudhary, PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3zeta signalosome and downstream signaling to PKCtheta, FEBS Lett. 574 (2004) 37-41.
7. M. Sznol, L. Chen, Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer, Clin. Cancer Res. 19 (2013) 1021-1034.
8. D.L. Barber, E.J. Wherry, D. Masopust, B. Zhu, J.P. Allison, A.H. Sharpe, G.J. Freeman, R. Ahmed, Restoring function in exhausted CD8 T cells during chronic viral infection, Nature 439 (2006) 682-687.
9. T.F. Gajewski, J. Louahed, V.G. Brichard, Gene signature in melanoma associated with clinical activity: a potential clue to unlock cancer immunotherapy, Cancer J. 16 (2010) 399-403.
10. Y. Zhang, S. Huang, D. Gong, Y. Qin, Q. Shen, Programmed death-1 upregulation is correlated with dysfunction of tumor-infiltrating CD8+ T lymphocytes in human non-small cell lung cancer, Cell. Mol. Immunol. 7 (2010) 389-395.
11. S.C. Liang, R.J. Greenwald, Y.E. Latchman, L. Rosas, A. Satoskar, G.J. Freeman, A.H. Sharpe, PD-L1 and PD-L2 have distinct roles in regulating host immunity to cutaneous leishmaniasis, Eur. J. Immunol. 36 (2006) 58-64.
12. C. Blank, I. Brown, R. Marks, H. Nishimura, T. Honjo, T.F. Gajewski, Absence of programmed death receptor 1 alters thymic development and enhances generation of CD4/CD8 double-negative TCR-transgenic T cells, J. Immunol. 171 (2003) 4574-4581 (Baltimore, Md: 1950).
13. Abstracts of the Society for Melanoma Research 2012 Congress. November 8-11, 2012. Hollywood, California, USA, Pigm. Cell Melanoma Res. 25 (2012) (2012) 836-903.
14. S.L. Topalian, M. Sznol, D.F. McDermott, H.M. Kluger, R.D. Carvajal, W.H. Sharfman, J.R. Brahmer, D.P. Lawrence, M.B. Atkins, J.D. Powderly, P.D. Leming, E.J. Lipson, I. Puzanov, D.C. Smith, J.M. Taube, J.M. Wigginton, G.D. Kollia, A. Gupta, D.M. Pardoll, J.A. Sosman, F.S. Hodi, Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab, J. Clin. Oncol. 32 (2014) 1020-1030.
15. J. Folkman, Tumor angiogenesis: therapeutic implications, N. Engl. J. Med. 285 (1971) 1182-1186.
16. F.S. Hodi, D. Lawrence, C. Lezcano, X. Wu, J. Zhou, T. Sasada, W. Zeng, A. Giobbie-Hurder, M.B. Atkins, N. Ibrahim, P. Friedlander, K.T. Flaherty, G.F. Murphy, S. Rodig, E.F. Velazquez, M.C. Mihm Jr., S. Russell, P.J. DiPiro, J.T. Yap, N. Ramaiya, A.D. Van den Abbeele, M. Gargano, D. McDermott, Bevacizumab plus ipilimumab in patients with metastatic melanoma, Cancer Immunol. Res. (2014)
17. D.J. Lyttle, K.M. Fraser, S.B. Fleming, A.A. Mercer, A.J. Robinson, Homologs of vascular endothelial growth factor are encoded by the poxvirus orf virus, J. Virol. 68 (1994) 84-92.
18. K. Alitalo, P. Carmeliet, Molecular mechanisms of lymphangiogenesis in health and disease, Cancer Cell 1 (2002) 219-227.
19. Y. Yamazaki, K. Takani, H. Atoda, T. Morita, Snake venom vascular endothelial growth factors (VEGFs) exhibit potent activity through their specific recognition of KDR (VEGF receptor 2), J. Biol. Chem. 278 (2003) 51985-51988.
20. H. Takahashi, S. Hattori, A. Iwamatsu, H. Takizawa, M. Shibuya, A novel snake venom vascular endothelial growth factor (VEGF) predominantly induces vascular permeability through preferential signaling via VEGF receptor-1, J. Biol. Chem. 279 (2004) 46304-46314.
21. G. Korpanty, L.A. Sullivan, E. Smyth, D.N. Carney, R.A. Brekken, Molecular and clinical aspects of targeting the VEGF pathway in tumors, J. Oncol. 2010 (2010) 652320.
22. N. Ferrara, H.P. Gerber, J. LeCouter, The biology of VEGF and its receptors, Nat. Med. 9 (2003) 669-676.
23. S. Takahashi, Vascular endothelial growth factor (VEGF), VEGF receptors and their inhibitors for antiangiogenic tumor therapy, Biol. Pharm. Bull. 34 (2011) 1785-1788.
24. G. Fuh, B. Li, C. Crowley, B. Cunningham, J.A. Wells, Requirements for binding and signaling of the kinase domain receptor for vascular endothelial growth factor, J. Biol. Chem. 273 (1998) 11197-11204.
25. C. Ruch, G. Skiniotis, M.O. Steinmetz, T. Walz, K. Ballmer-Hofer, Structure of a VEGF-VEGF receptor complex determined by electron microscopy, Nat. Struct. Mol. Biol. 14 (2007) 249-250.
26. J.A. Nagy, A.M. Dvorak, H.F. Dvorak, VEGF-A and the induction of pathological angiogenesis, Ann. Rev. Pathol. 2 (2007) 251-275.
27. M. Shibuya, Vascular endothelial growth factor and its receptor system: physiological functions in angiogenesis and pathological roles in various diseases, J. Biochem. 153 (2013) 13-19.
28. D.I. Gabrilovich, T. Ishida, S. Nadaf, J.E. Ohm, D.P. Carbone, Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function, Clin. Cancer Res. 5 (1999) 2963-2970.
29. B. Seliger, C. Massa, B. Rini, J. Ko, J. Finke, Antitumour and immune-adjuvant activities of protein-tyrosine kinase inhibitors, Trends Mol. Med. 16 (2010) 184-192.
30. R. Tom, L. Bisson, Y. Durocher, Culture of HEK293-EBNA1 cells for production of recombinant proteins, CSH Protoc. (2008) pdb prot4976.